Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma. (Q37181235)
Jump to navigation
Jump to search
scientific article published on 25 March 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma. |
scientific article published on 25 March 2011 |
Statements
Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma (English)
S Tariq Mahmood
Samuel Agresta
Carlos E Vigil
Xiuhua Zhao
Gina D'Amato
Ciara E Calitri
Michelle Dean
Christopher Garrett
Michael J Schell
Scott Antonia
Alberto Chiappori
1 reference
1 reference
1 reference